Skip to main content
Anteris Technologies Global Corp. logo

Anteris Technologies Global Corp. — Investor Relations & Filings

Ticker · AVR ISIN · US03675P1021 ASX Manufacturing
Open in API
Filings indexed 1,664 across all filing types
Latest filing 2020-03-23 Director's Dealing
Country US United States of America
Listing ASX AVR

About Anteris Technologies Global Corp.

https://anteristech.com/

Anteris Technologies is a structural heart company focused on the development and commercialization of medical devices for heart valve disease. Its lead product is the DurAVR® Transcatheter Heart Valve (THV), a biomimetic valve designed for patients with severe aortic stenosis. The DurAVR® THV is engineered to mimic the performance of a healthy human aortic valve, aiming to restore normal, laminar blood flow. Clinical studies have shown the device delivers a favorable hemodynamic profile, characterized by low pressure gradients and a significant reduction in prosthesis-patient mismatch (PPM), even in patients with challenging anatomies. The company is advancing its technology through pivotal clinical trials to establish a new standard in transcatheter aortic valve replacement (TAVR) and improve long-term patient outcomes.

Recent filings

Filing Released Lang Actions
Change of Director's Interest Notice 9 pages 620.2KB
Director's Dealing Classification · 100% confidence The document is titled 'Appendix 3Y Change of Director’s Interest Notice' and contains detailed disclosures about changes in directors' relevant interests in securities, including the number of shares and options held before and after the change, dates of changes, and nature of the changes. It references ASX listing rule 3.19A.2 and section 205G of the Corporations Act, which govern director's interest disclosures. The document is not a financial report, earnings release, or management discussion but a regulatory filing specifically reporting personal share transactions by company directors. This matches the definition of 'Director's Dealing' filings. The document length is over 12,000 characters and contains substantive data about director share transactions, not just an announcement or certification. Therefore, the correct classification is 'DIRS' (Director's Dealing).
2020-03-23 English
Proposed issue of Securities - AHZ 5 pages 28.0KB
Capital/Financing Update Classification · 95% confidence The document is an announcement regarding a proposed issue of securities by ADMEDUS LTD. It details the type of securities to be issued, the number of securities, the issue price, approval dates, and conditions related to the issuance. There is no financial performance data, management discussion, or audit information. The document is focused on informing about a capital raising event or placement of securities. This fits the definition of a Capital/Financing Update (CAP). The document length is over 6000 characters and contains detailed information about the securities issue, not just a brief notice or a report publication announcement. Therefore, the correct classification is CAP with high confidence.
2020-03-22 English
Coronavirus Mitigation Strategy 2 pages 117.9KB
Regulatory Filings Classification · 95% confidence The document is an ASX announcement dated 20 March 2020 regarding the company's coronavirus mitigation strategy. It discusses operational impacts, manufacturing continuity, and adjustments to corporate practices due to COVID-19. There are no financial statements, earnings data, or detailed financial analysis present. The document is relatively short (2925 characters) and serves as an operational update rather than a financial report or regulatory filing. It does not fit into categories like Annual Report, Interim Report, Earnings Release, or Management Reports. It is also not a report publication announcement or certification. The content is best classified as a general regulatory announcement about operational strategy and risk mitigation, which fits the Regulatory Filings (RNS) category as a fallback for miscellaneous announcements that do not fit other specific categories.
2020-03-19 English
Notice of Annual General Meeting and Director Nominations 2 pages 188.7KB
AGM Information Classification · 95% confidence The document is an ASX announcement dated 19 March 2020 regarding the Notice of Annual General Meeting (AGM) and Director Nominations for Admedus Ltd. It specifies the date, time, and location of the AGM and details about director nominations. The document is short (1930 characters) and serves as a notice rather than containing any AGM materials or presentations. It is not a full Annual Report, nor an earnings release or other financial report. It is clearly a notice related to the AGM event itself, specifically about the meeting and director nominations. Therefore, the appropriate classification is AGM Information (AGM-R).
2020-03-18 English
Approval for first-in-human study 1 page 122.1KB
Regulatory Filings Classification · 95% confidence The document is an ASX announcement dated 11 March 2020 regarding Admedus Limited receiving final approval from the Federal Agency for Medicines and Health Products (FAMHP) for a first-in-human study. The content is a brief announcement about regulatory approval to proceed with a clinical study, with no financial data, no detailed report, and no mention of financial results or management discussion. The document length is short (2011 characters), and it serves as a regulatory update or announcement rather than a full report or detailed filing. It does not fit categories like Annual Report, Interim Report, Earnings Release, or Management Reports. It is not a proxy, voting result, or capital change announcement. The best fitting category is Regulatory Filings (RNS), which is the fallback for miscellaneous regulatory announcements that do not fit other categories.
2020-03-10 English
Appendix 4E and Full Year Accounts 83 pages 1.5MB
Annual Report Classification · 95% confidence The document is titled 'Appendix 4E (Rule 4.3a)' and is from Admedus Ltd for the financial year ended 31 December 2019. It contains detailed financial results, including revenue, loss, dividends, net tangible asset backing, and a comprehensive Directors' Report. The document includes consolidated financial statements, notes, auditor's report, and corporate governance statement. It discusses operating results, financial position, cash flow, business risks, and significant transactions such as divestments and sales of business units. The length is about 15,000 characters, indicating a full report rather than a brief announcement. The content and structure align with an official yearly report covering company activity and full financial performance, consistent with an Annual Report (10-K equivalent). There is no indication that this is merely an announcement or a certification, nor is it a quarterly or interim report. Therefore, the document is best classified as an Annual Report (10-K). FY 2019
2020-02-27 English

Browse filings by year

23 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.